SCHEMBL16202078

SCHEMBL16202078

Cc1ccn(-c2cccc(Oc3ccc(Cl)cc3)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 5/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 2/20 0.37
ALPG P10696 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16202076 0.88 MAPT (0.46) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL2615990 0.80 NOTUM (0.53) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL5963053 0.79 HTT (0.49) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL24378467 0.79 NOTUM (0.57) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL14412226 0.78 RAB9A (0.59) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL2615994 0.76 HTT (0.56) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL5101204 0.73 MEN1 (0.56) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL16890736 0.72 ALDH1A1 (0.60) MAPTSMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL3296777 0.71 ALDH1A1 (0.67) MAPTSMN1; SMN2L3MBTL1ALDH1A1KMT2A
SCHEMBL22796241 0.71 HTT (0.50) MAPTSMN1; SMN2RAB9ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 MAPT 1798/4885SMN1; SMN2 2653/4885RAB9A 2110/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 MAPT 1392/4885SMN1; SMN2 3486/4885RAB9A 2327/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 MAPT 1392/4885SMN1; SMN2 3486/4885RAB9A 2327/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB MAPT 2644/4885SMN1; SMN2 2724/4885RAB9A 1342/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB MAPT 2644/4885SMN1; SMN2 2724/4885RAB9A 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.